FDA Panel Recommends Approval For Pulmonary Hypertension Drug From Bayer

The FDA’s Cardiovascular and Renal Drugs Advisory Committee recommended approval for Bayer’s new pulmonary hypertension drug, riociguat. The committee voted 11-0 in favor of approving the drug for two forms of pulmonary hypertension: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPH).

Click here to read the full story on Forbes.

 

 

 

 

Leave a Reply

%d bloggers like this: